Herceptin Sc 600 mg Concentrate for solution for infusion
PDF Leaflet Revision Date: 23 December 2022
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of HER2 positive breast cancer.
Dosage (summary)
600 mg subcutaneously every 3 weeks.
Special Populations
- Elderly
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Contraindicated in pregnancy and breastfeeding.
Contraindications
- Hypersensitivity to trastuzumab
- Severe dyspnoea at rest
Common side effects
- Cardiotoxicity
- Hypersensitivity reactions
- Neutropenia
Counselling Points
- Monitor for cardiac function
- Avoid during pregnancy
- Report any infusion reactions
Serious warnings
- Risk of cardiomyopathy
- Severe hypersensitivity reactions
Important Disclaimer
The Herceptin Sc 600 mg Concentrate for solution for infusion professional information leaflet below is the property of Roche Products and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
